Rosiglitazone prior authorization safety policy: A cohort study

Journal of Managed Care Pharmacy

Volumn 18, Issue 3, 2012, Pages 225-233

  Starner, Catherine I ^a   Fenrick, Beckie ^b   Coleman, John ^c   Wickersham, Peter ^a   Gleason, Patrick P ^a  

^a Prime Therapeutics LLC   (United States)

^b Pharmacy Care Models and Affordability Solutions   (United States)

^c Blue Cross Blue Shield of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; NITRATE; ROSIGLITAZONE;

ADULT; ARTICLE; BULIMIA; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG LEGISLATION; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; POLYDIPSIA; POLYURIA; PRIOR AUTHORIZATION;

EID: 84860736930     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.3.225     Document Type: Article

References (34)

1. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm. 2001;7(4):297-302. Available at: http://www.amcp.org/data/jmcp/Review-297-302.pdf.
2. Fallik B. The Academy of Managed Care Pharmacy's concepts in managed care pharmacy: prior authorization and the formulary exception process. J Manag Care Pharm. 2005;11(4):358-61. Available at: http://www.amcp.org/data/jmcp/Letters_358-3611.pdf.
3. Pharmacy Benefit Management Institute. Prescription Drug Benefit Cost and Plan Design Online Report. 2011-2012 ed. Available at: http://www.benefitdesignreport.com/. Accessed February 20, 2012.
4. Academy of Managed Care Pharmacy, Shoemaker SJ, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16(6 Suppl):S1-S20. Available at: http://www.amcp.org/data/jmcp/JulSuppA.pdf.
5. Delate T, Mager DE, Sheth J, et al. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36.
6. Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169(8):750-56. Available at: http://archinte.ama-assn.org/cgi/content/full/169/8/750. Accessed February 20, 2012.
7. Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520-27.
8. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59(5):540-46.
9. McCombs JS, Shi L, Stimmel GL, Croghan, TW. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther. 2002;24(11):1939-59.
10. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-94. Available at: http://www.nejm.org/doi/full/10.1056/NEJMsa042770. Accessed February 20, 2012.
11. Gleason PP, Williams C, Hrdy S, et al. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Pharmacotherapy. 2005;25(7):924-34.
12. Hartung DM, Touchette DR, Ketchum KL, et al. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther. 2004;26(9):1518-32.
13. Stacy J, Shaw E, Arledge MD, Howell-Smith D. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. J Manag Care Pharm. 2003;9(4):327-34. Available at: http://www.amcp.org/data/jmcp/Research-327-334.pdf.
14. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15(10):e95-e102.
15. Zeng F, Chen C, Mastey V, et al. Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis. Am J Manag Care. 2010;16(9):667-74.
16. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care. 2010;48(1):4-9.
17. Walthour A, Seymour L, Tackett R, et al. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents. Ann Pharmacother. 2010;44(5):809-18.
18. Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. J Manag Care Pharm. 2010;16(1):15-22. Available at: http://www.amcp.org/data/jmcp/15-22.pdf.
19. Avandia (rosiglitazone) prescribing information. GlaxoSmithKline, Research Triangle Park, NC. 2007. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf. Accessed February 20, 2012.
20. U.S. Food and Drug Administration. FDA drug safety communication: reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program. November 4, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm277629.htm. Accessed on February 20, 2012.
21. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
22. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association, European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203. Available at: http://care.diabetesjournals.org/content/32/1/193.long. Accessed February 20, 2012.
23. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14(6):523-31. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_523-531.pdf.
24. Ostini R, Hegney D, Jackson C, Tett SE. Knowing how to stop: ceasing prescribing when the medicine is no longer required. J Manag Care Pharm. 2012;18(1):68-72. Available at: http://www.amcp.org/JMCP/2012/January-February/14486/1033.html.
25. Ross JS, Jackevicius C, Krumholz HM, et al. State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. Health Aff (Millwood). 2012;31(1):188-98.
26. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-43.
27. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16(6):447-56.
28. Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Eng J Med. 2008;359(17):1802-10. Available at: http://www.nejm.org/doi/full/10.1056/NEJMsa0803410. Accessed February 20, 2012.
29. Jackson MA, Fairman KA, Curtiss FA. Prior authorization and clopidogrel use-the truth lies in the details. J Manag Care Pharm. 2009;15(1):71-77. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8058.
30. Jacobson Vann JC, Christofferson S, Humble CG, Wegner SE, Feaganes JR, Trygstad TK. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program. J Manag Care Pharm. 2010;16(4):250-63. Available at: http://www.amcp.org/data/jmcp/250-263.pdf.
31. Morden NE, Zerzan JT, Rue TC, et al. Medicaid prior authorization and controlled-release oxycodone. Med Care. 2008;46(6):573-80.
32. Law MR, Lu CY, Soumerai SB, et al. Impact of two Medicaid priorauthorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2010;32(4):729-41.
33. Lu CY, Law MR, Soumerai SB, et al. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2011;33(1):135-44.
34. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning-geographic variation in the use of rosiglitazone. N Eng J Med. 2010;363(22):2081-84. Available at: http://www.nejm.org/doi/full/10.1056/NEJMp1011042. Accessed February 20, 2012.